NITINOL BUSINESS acquired by RESONETICS
Context
The takeover of the SAES Getters Nitinol business by Resonetics establishes a rare, end-to-end metallurgical capability within the medical CDMO landscape. By absorbing the complete production chain—from the furnace to the finished catheter component—the organization bypasses the traditional constraints of specialized material procurement. This strategic consolidation addresses a critical bottleneck in the interventional device market, where high-grade Nitinol supply often dictates project timelines. Beyond simple supply chain security, the integration enables a deeper level of innovation; the group can now customize alloy chemistry to optimize the mechanical response of next-generation stents and heart valves. This move effectively insulates the platform from upstream price volatility and technical dependencies on external metal suppliers. By merging raw alloy science with precision laser-cutting expertise, the group offers a unique, high-security value proposition to global medtech OEMs.
NITINOL BUSINESS, which reported an EBITDA margin of in 2023, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).
-> Deep-dive in Healthcare & Pharma market trends
Target
The Nitinol Business (Memry & SAES Smart Materials) is a United States organization specialized in Nitinol Medical Components. The entity operates as a technologically advanced leader in the development and manufacturing of next-generation, highly engineered medical components utilizing Nitinol shape memory alloys. At the heart of their operations is a philosophy of vertical integration, maintaining total control over the production process from the initial melting of the alloy to the final precision fabrication of medical components. They differentiate themselves through their mastery of super-elasticity and shape memory properties, which are essential for minimally invasive medical devices and life science applications.
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (USD)
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 11/2023 | ANJAC BEAUTY & HEALTH | STEPHID | FRANCE | CDMO |
| 11/2023 | AMETEK | PARAGON MEDICAL | UNITED STATES | Medical Devices |
| 10/2023 | LUXEMPART | ALPHACAPS | GERMANY | Nutrition & Dietary Supplements |
| 08/2023 | ATHOS CONSORTIUM | SCHÜLKE | GERMANY | Medical Consumables |
| 08/2023 | OAKLEY CAPITAL INVESTMENTS | LIBERTY DENTAL GROUP | GERMANY | Implants & Prosthetics |
| 08/2023 | CARL ZEISS MEDITEC | D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) | NETHERLANDS | Medical Devices |
| 07/2023 | EQT PARTNERS / ADIA | DECHRA PHARMACEUTICALS | UNITED KINGDOM | Pharma & Biotech |
| 07/2023 | LAUXERA | ORGANOX | UNITED KINGDOM | Medical Devices |
| 07/2023 | ELOS MEDTECH | KLINGEL MEDICAL GROUP | GERMANY | Implants & Prosthetics |
| 06/2023 | NOVO NORDISK | BIOCORP | FRANCE | Medical Devices |
REFERENCES
Valuation range: EV 500M - 1.5b USD
Revenue range: 100M - 200M USD
EBITDA range: 50M - 100M USD
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of NITINOL BUSINESS by RESONETICS are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Acquirer: resonetics